Abstract：
OBJECTIVE: Eravacycline, a new tetracycline derivative, exhibits broad-spectrum antimicrobial susceptibility. This study aimed to comprehensively investigate in vitro activities of eravacycline, tigecycline, and ertapenem against various Gram-positive, Gram-negative, and anaerobic bacteria.
METHODS: Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. The following bacterial species were collected: vancomycin-sensitive (VS) Enterococci species, vancomycin-resistant Enterococci species (VRE), Staphylococcus aureus, Streptococcus anginosus, Bacteroides species, Clostridioides difficile, Clostridium innocuum, Clostridium perfringens, Parabacteroides distasonis, and Stenotrophomonas maltophilia.
RESULTS: We found that eravacycline exhibited superior in vitro activity compared to tigecycline and ertapenem. Notably, it exhibited the lowest MIC90 for several bacterial species, including VS E. faecalis (0.12 µg/mL), VS E. faecium (0.12 µg/mL), and others. Besides, VRE was susceptible to eravacycline (MIC90:0.12 µg/mL) and tigecycline (MIC90:0.12 µg/mL), but was all resistant to ertapenem (MIC90 > 64 µg/mL). S. aureus was also susceptible to eravacycline (MIC90:0.5 µg/mL) as well as tigecycline (MIC90:1.0 µg/mL). Furthermore, S. anginosus showed higher susceptibility to eravacycline (MIC90:2.0 µg/mL) and tigecycline (MIC90:4.0 µg/mL), but lower to ertapenem (MIC90:32.0 µg/mL). Eravacycline and tigecycline also demonstrated good susceptibility to anaerobes, including Bacteroides species (susceptibility rate: 100%), P. distasonis (100%), C. difficile (94.1‒100%), C. innocuum (94.1‒96.1%), and C. perfringens (88.9‒96.3%). For S. maltophilia, both tigecycline and eravacycline showed an MIC90 of 2 µg/mL. A moderate-to-strong correlation (rho = 0.608-0.804, P < 0.001) was noted between the MIC values of eravacycline and tigecycline against various bacterial species.
CONCLUSIONS: Our study highlights the potential of eravacycline as an effective treatment option for multidrug-resistant bacterial infections.
METHODS: Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. The following bacterial species were collected: vancomycin-sensitive (VS) Enterococci species, vancomycin-resistant Enterococci species (VRE), Staphylococcus aureus, Streptococcus anginosus, Bacteroides species, Clostridioides difficile, Clostridium innocuum, Clostridium perfringens, Parabacteroides distasonis, and Stenotrophomonas maltophilia.
RESULTS: We found that eravacycline exhibited superior in vitro activity compared to tigecycline and ertapenem. Notably, it exhibited the lowest MIC90 for several bacterial species, including VS E. faecalis (0.12 µg/mL), VS E. faecium (0.12 µg/mL), and others. Besides, VRE was susceptible to eravacycline (MIC90:0.12 µg/mL) and tigecycline (MIC90:0.12 µg/mL), but was all resistant to ertapenem (MIC90 > 64 µg/mL). S. aureus was also susceptible to eravacycline (MIC90:0.5 µg/mL) as well as tigecycline (MIC90:1.0 µg/mL). Furthermore, S. anginosus showed higher susceptibility to eravacycline (MIC90:2.0 µg/mL) and tigecycline (MIC90:4.0 µg/mL), but lower to ertapenem (MIC90:32.0 µg/mL). Eravacycline and tigecycline also demonstrated good susceptibility to anaerobes, including Bacteroides species (susceptibility rate: 100%), P. distasonis (100%), C. difficile (94.1‒100%), C. innocuum (94.1‒96.1%), and C. perfringens (88.9‒96.3%). For S. maltophilia, both tigecycline and eravacycline showed an MIC90 of 2 µg/mL. A moderate-to-strong correlation (rho = 0.608-0.804, P < 0.001) was noted between the MIC values of eravacycline and tigecycline against various bacterial species.
CONCLUSIONS: Our study highlights the potential of eravacycline as an effective treatment option for multidrug-resistant bacterial infections.
摘要：
目标：埃拉瓦环素，一种新的四环素衍生物，表现出广谱抗微生物敏感性。本研究旨在全面考察埃拉环素的体外活性,替加环素,和厄他培南对抗各种革兰氏阳性，革兰氏阴性,和厌氧细菌。
方法:使用肉汤微量稀释法测定最小抑制浓度(MIC)。收集了以下细菌物种：万古霉素敏感（VS）肠球菌物种，耐万古霉素肠球菌（VRE），金黄色葡萄球菌,硬化链球菌,拟杆菌属物种，艰难梭菌，无菌梭菌,产气荚膜梭菌,双分支杆菌,和嗜麦芽窄食单胞菌.
结果：我们发现，与替加环素和厄他培南相比，埃拉环素表现出优异的体外活性。值得注意的是,它显示了几种细菌的最低MIC90，包括VS粪肠球菌(0.12μg/mL)，VS屎肠球菌(0.12μg/mL)，和其他人。此外,VRE对埃拉环素（MIC90：0.12μg/mL）和替加环素（MIC90：0.12μg/mL）敏感，但均对厄他培南耐药(MIC90>64μg/mL)。金黄色葡萄球菌也对埃拉环素(MIC90:0.5μg/mL)以及替加环素(MIC90:1.0μg/mL)敏感。此外，对埃拉环素（MIC90：2.0μg/mL）和替加环素（MIC90：4.0μg/mL）的敏感性更高，但低于厄他培南（MIC90：32.0μg/mL）。伊拉伐环素和替加环素也表现出对厌氧菌的良好敏感性，包括拟杆菌属物种（敏感率：100％），P.Distasonis（100%），艰难C.(94.1-100%)，C.无毒（94.1-96.1％），产气荚膜梭菌（88.9-96.3%）。对于嗜麦芽嗜血杆菌,替加环素和埃拉环素的MIC90均为2μg/mL.在埃拉环素和替加环素对各种细菌物种的MIC值之间注意到中等到强的相关性(rho=0.608-0.804,P<0.001)。
结论：我们的研究强调了埃拉环素作为多药耐药细菌感染的有效治疗选择的潜力。
方法:使用肉汤微量稀释法测定最小抑制浓度(MIC)。收集了以下细菌物种：万古霉素敏感（VS）肠球菌物种，耐万古霉素肠球菌（VRE），金黄色葡萄球菌,硬化链球菌,拟杆菌属物种，艰难梭菌，无菌梭菌,产气荚膜梭菌,双分支杆菌,和嗜麦芽窄食单胞菌.
结果：我们发现，与替加环素和厄他培南相比，埃拉环素表现出优异的体外活性。值得注意的是,它显示了几种细菌的最低MIC90，包括VS粪肠球菌(0.12μg/mL)，VS屎肠球菌(0.12μg/mL)，和其他人。此外,VRE对埃拉环素（MIC90：0.12μg/mL）和替加环素（MIC90：0.12μg/mL）敏感，但均对厄他培南耐药(MIC90>64μg/mL)。金黄色葡萄球菌也对埃拉环素(MIC90:0.5μg/mL)以及替加环素(MIC90:1.0μg/mL)敏感。此外，对埃拉环素（MIC90：2.0μg/mL）和替加环素（MIC90：4.0μg/mL）的敏感性更高，但低于厄他培南（MIC90：32.0μg/mL）。伊拉伐环素和替加环素也表现出对厌氧菌的良好敏感性，包括拟杆菌属物种（敏感率：100％），P.Distasonis（100%），艰难C.(94.1-100%)，C.无毒（94.1-96.1％），产气荚膜梭菌（88.9-96.3%）。对于嗜麦芽嗜血杆菌,替加环素和埃拉环素的MIC90均为2μg/mL.在埃拉环素和替加环素对各种细菌物种的MIC值之间注意到中等到强的相关性(rho=0.608-0.804,P<0.001)。
结论：我们的研究强调了埃拉环素作为多药耐药细菌感染的有效治疗选择的潜力。
